{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:40:56Z","timestamp":1762782056611},"reference-count":110,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Breakpoint cluster region-Abelson (<\/jats:p>","DOI":"10.1515\/cclm-2016-0927","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:26:24Z","timestamp":1487687184000},"source":"Crossref","is-referenced-by-count":7,"title":["A review of the challenge in measuring and standardizing BCR-ABL1"],"prefix":"10.1515","volume":"55","author":[{"given":"Shuping","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref851","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1373\/clinchem.2014.228304","article-title":"Extreme PCR: efficient and specific DNA amplification in 15\u201360 seconds","volume":"61","year":"2015","journal-title":"Clin Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","year":"1962","journal-title":"Blut"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4065\/79.1.58","article-title":"Primer on medical genomics. Part XI: Visualizing human chromosomes","volume":"79","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","year":"1996","journal-title":"Blood"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"ref321","first-page":"899","article-title":"Performance criteria for reference measurement procedures and reference materials","volume":"53","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","year":"2013","journal-title":"Clin Chem"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","year":"2012","journal-title":"Leukemia"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","year":"2012","journal-title":"Leukemia"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","year":"2002","journal-title":"Cancer Cell"},{"key":"ref661","first-page":"971","article-title":"A rapid banding technique for human chromosomes","volume":"2","year":"1971","journal-title":"Lancet"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bios.2012.05.010","article-title":"Chitosan encapsulated quantum dots platform for leukemia detection","volume":"38","year":"2012","journal-title":"Biosens Bioelectron"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","year":"2010","journal-title":"Blood"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/JCM.36.12.3590-3594.1998","article-title":"Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards","volume":"36","year":"1998","journal-title":"J Clin Microbiol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","year":"2008","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","year":"2010","journal-title":"Blood"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","year":"2013","journal-title":"Blood"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","year":"2013","journal-title":"Clin Chem"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/med.1022","article-title":"Tyrosine kinase inhibitors: from rational design to clinical trials","volume":"21","year":"2001","journal-title":"Med Res Rev"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-0733-5_4","article-title":"Introduction to digital PCR","volume":"1160","year":"2014","journal-title":"Methods Mol Biol"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","year":"2007","journal-title":"Clin Chem"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","year":"2010","journal-title":"Blood"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay","volume":"131","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","year":"2009","journal-title":"Haematologica"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-0733-5_4","article-title":"Introduction to digital PCR","volume":"1160","year":"2014","journal-title":"Methods Mol Biol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]","volume":"243","year":"1973","journal-title":"Nature"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/ac902398c","article-title":"Spinning disk platform for microfluidic digital polymerase chain reaction","volume":"82","year":"2010","journal-title":"Anal Chem"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4065\/77.8.785","article-title":"Primer on medical genomics part II: background principles and methods in molecular genetics","volume":"77","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","year":"1962","journal-title":"Blut"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","year":"2006","journal-title":"J Mol Diagn"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1471-4914(03)00047-9","article-title":"Quantitative real-time PCR: a powerful ally in cancer research","volume":"9","year":"2003","journal-title":"Trends Mol Med"},{"key":"ref411","first-page":"570","article-title":"A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system","volume":"47","year":"2015","journal-title":"Pathology"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","article-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia","volume":"7","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4065\/79.1.58","article-title":"Primer on medical genomics. Part XI: Visualizing human chromosomes","volume":"79","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/109.1.24","article-title":"A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias","volume":"109","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2009.93","article-title":"Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients","volume":"23","year":"2009","journal-title":"Leukemia"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2013 a Europe against cancer program","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.leu.2403590","article-title":"Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol","volume":"19","year":"2005","journal-title":"Leukemia"},{"key":"ref371","first-page":"534","article-title":"Evaluation of clinical performance of the major BCR-ABL mRNA detection kit which enables conversion to international standard scale using the reference material calibrator","volume":"55","year":"2014","journal-title":"Rinsho Ketsueki"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2013 a Europe against cancer program","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","year":"2004","journal-title":"Blood"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","year":"2002","journal-title":"Cancer Cell"},{"key":"ref871","first-page":"899","article-title":"Performance criteria for reference measurement procedures and reference materials","volume":"53","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.leu.2403590","article-title":"Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol","volume":"19","year":"2005","journal-title":"Leukemia"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","year":"2013","journal-title":"Blood"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","year":"2006","journal-title":"J Mol Diagn"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","year":"2006","journal-title":"Blood"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/ac902398c","article-title":"Spinning disk platform for microfluidic digital polymerase chain reaction","volume":"82","year":"2010","journal-title":"Anal Chem"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jviromet.2008.02.007","article-title":"The use of Armored RNA as a multi-purpose internal control for RT-PCR","volume":"150","year":"2008","journal-title":"J Virol Methods"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762)","volume":"80","year":"1992","journal-title":"Blood"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1620\/tjem.214.97","article-title":"Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan","volume":"214","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bios.2012.05.010","article-title":"Chitosan encapsulated quantum dots platform for leukemia detection","volume":"38","year":"2012","journal-title":"Biosens Bioelectron"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1373\/clinchem.2014.228304","article-title":"Extreme PCR: efficient and specific DNA amplification in 15\u201360 seconds","volume":"61","year":"2015","journal-title":"Clin Chem"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","article-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia","volume":"7","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay","volume":"131","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/0377-4929.101742","article-title":"Fluorescence in situ hybridization patterns of BCR\/ABL1 fusion in chronic myelogenous leukemia at diagnosis","volume":"55","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"ref171","first-page":"181","article-title":"A nested RT-PCR assay to detect BCR\/abl","volume":"97","year":"2004","journal-title":"Methods Mol Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","year":"2004","journal-title":"Blood"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","year":"2010","journal-title":"Blood"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5858\/arpa.2013-0754-OA","article-title":"Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing","volume":"139","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"ref671","first-page":"311","article-title":"Interphase FISH studies of chronic myeloid leukemia","volume":"204","year":"2002","journal-title":"Methods Mol Biol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","year":"2008","journal-title":"Blood"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/109.1.24","article-title":"A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias","volume":"109","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2009.93","article-title":"Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients","volume":"23","year":"2009","journal-title":"Leukemia"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","year":"2006","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1471-4914(03)00047-9","article-title":"Quantitative real-time PCR: a powerful ally in cancer research","volume":"9","year":"2003","journal-title":"Trends Mol Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","year":"1996","journal-title":"Blood"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","year":"2009","journal-title":"Haematologica"},{"key":"ref111","first-page":"971","article-title":"A rapid banding technique for human chromosomes","volume":"2","year":"1971","journal-title":"Lancet"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","year":"2011","journal-title":"Blood"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jviromet.2008.02.007","article-title":"The use of Armored RNA as a multi-purpose internal control for RT-PCR","volume":"150","year":"2008","journal-title":"J Virol Methods"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.clinbiochem.2014.05.067","article-title":"Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale","volume":"47","year":"2014","journal-title":"Clin Biochem"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5858\/arpa.2013-0754-OA","article-title":"Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing","volume":"139","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1620\/tjem.214.97","article-title":"Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan","volume":"214","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","year":"2007","journal-title":"Clin Chem"},{"key":"ref121","first-page":"311","article-title":"Interphase FISH studies of chronic myeloid leukemia","volume":"204","year":"2002","journal-title":"Methods Mol Biol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.clinbiochem.2014.05.067","article-title":"Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale","volume":"47","year":"2014","journal-title":"Clin Biochem"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"ref721","first-page":"181","article-title":"A nested RT-PCR assay to detect BCR\/abl","volume":"97","year":"2004","journal-title":"Methods Mol Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"ref921","first-page":"534","article-title":"Evaluation of clinical performance of the major BCR-ABL mRNA detection kit which enables conversion to international standard scale using the reference material calibrator","volume":"55","year":"2014","journal-title":"Rinsho Ketsueki"},{"key":"ref961","first-page":"570","article-title":"A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system","volume":"47","year":"2015","journal-title":"Pathology"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","year":"2011","journal-title":"Blood"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]","volume":"243","year":"1973","journal-title":"Nature"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4065\/77.8.785","article-title":"Primer on medical genomics part II: background principles and methods in molecular genetics","volume":"77","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/med.1022","article-title":"Tyrosine kinase inhibitors: from rational design to clinical trials","volume":"21","year":"2001","journal-title":"Med Res Rev"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/0377-4929.101742","article-title":"Fluorescence in situ hybridization patterns of BCR\/ABL1 fusion in chronic myelogenous leukemia at diagnosis","volume":"55","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762)","volume":"80","year":"1992","journal-title":"Blood"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/JCM.36.12.3590-3594.1998","article-title":"Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards","volume":"36","year":"1998","journal-title":"J Clin Microbiol"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2017.55.issue-10\/cclm-2016-0927\/cclm-2016-0927.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2016-0927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T14:09:08Z","timestamp":1658671748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2016-0927\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":110,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1515\/cclm-2016-0927","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}